MedTrace Logo

The Research of Ammoxetine Hydrochloride Enteric-coated Tablets in Subjects With Depression

NCT06827431 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 770

Last updated 2025-02-14

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of Ammoxetine hydrochloride enteric-coated tablets in subjects with depression.

Conditions

  • Major Depressive Disorder (MDD)

Interventions

DRUG

Ammoxetine

Drug: Ammoxetine Ammoxetine hydrochloride enteric-coated tablets Drug: Placebo placebo to Ammoxetine and Sertraline.

DRUG

Ammoxetine

Drug: Ammoxetine Ammoxetine hydrochloride enteric-coated tablets Drug: Placebo placebo to Sertraline.

DRUG

Placebo

Drug: Placebo placebo to Ammoxetine hydrochlorid and Sertraline.

DRUG

Sertraline

Drug: Sertraline positive control Drug: Placebo placebo to Ammoxetine hydrochlorid.

Sponsors & Collaborators

  • CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-14
Primary Completion
2026-06-30
Completion
2026-09-30

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06827431 on ClinicalTrials.gov